

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

10 Jun 2026

### Comparison of the effectiveness of selenium with placebo on disease activity and inflammatory factors and oxidative stress in patients with rheumatoid arthritis

#### Protocol summary

##### Study aim

The aim of this study is to determine the effect of selenium supplementation on disease activity and inflammatory factors and oxidative stress in rheumatoid arthritis patients

##### Design

A double-blind placebo-controlled clinical trial. Patients will be assigned to either a selenium supplement (n = 30) or a placebo (n = 30).

##### Settings and conduct

Among the patients with rheumatoid arthritis referred to the Beheshti Clinic, 60 patients will be selected based on inclusion and exclusion criteria. Participants and researchers are unaware of the allocation of study groups. Supplement and placebo tablets are similar in shape and size. Fasting blood samples will be taken from patients at baseline and 12 weeks after intervention

##### Participants/Inclusion and exclusion criteria

rheumatoid arthritis patients; ages 18 to 75 years who  
Exclusion criteria: Patients with infectious diseases, concomitant rheumatologic disease or hypertension

##### Intervention groups

Intervention group: 200 µg daily selenium for 12 weeks.  
Control group: placebo tablet daily for 12 weeks

##### Main outcome variables

Changes in disease activity, changes in clinical symptoms, lipid profiles, inflammatory factors, and changes in oxidative stress biomarkers

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20190924044869N1**  
Registration date: **2020-06-14, 1399/03/25**  
Registration timing: **registered\_while\_recruiting**

Last update: **2020-06-14, 1399/03/25**

Update count: **0**

##### Registration date

2020-06-14, 1399/03/25

##### Registrant information

###### Name

Fereshteh Taghvaei

###### Name of organization / entity

###### Country

Iran (Islamic Republic of)

###### Phone

+98 31 5531 6850

###### Email address

sedaghat\_h@kaums.ac.ir

##### Recruitment status

###### Recruitment complete

##### Funding source

##### Expected recruitment start date

2020-02-20, 1398/12/01

##### Expected recruitment end date

2020-12-20, 1399/09/30

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

##### Scientific title

Comparison of the effectiveness of selenium with placebo on disease activity and inflammatory factors and oxidative stress in patients with rheumatoid arthritis

##### Public title

Effect of Selenium supplementation in rheumatoid arthritis

##### Purpose

Treatment

**Inclusion/Exclusion criteria**

**Inclusion criteria:**  
patients with active rheumatoid arthritis aged 18 to 75 years.

**Exclusion criteria:**  
active infection high and moderate blood pressure (systolic pressure less than 140 and diastolic pressure less than 90 mmHg) smoking concurrent rheumatologic disease Hypothyroidism or hyperthyroidism Kidney or liver failure

**Age**  
From **18 years** old to **75 years** old

**Gender**  
Both

**Phase**  
3

**Groups that have been masked**

- Participant
- Investigator

**Sample size**  
Target sample size: **60**

**Randomization (investigator's opinion)**  
Randomized

**Randomization description**  
Patients will be randomly assigned into two groups. A randomization list will be generated from 1 to 66 by a random number generator (<https://stattrek.com/statistics/random-number-generator.aspx>) and patients were randomly assigned into each intervention group by their numbers. The block randomization technique with 1:1 ratio will be used to achieve balanced group sizes. Supplements and placebos are in the same packaging at the Pharmaceutical company. Only the code is written on the packages. Patients and researchers do not know the type of intervention and after analyzing the data, packet codes are decoded.

**Blinding (investigator's opinion)**  
Double blinded

**Blinding description**  
Participants, investigators or the assessors of the outcomes are unaware of the study groups.

**Placebo**  
Used

**Assignment**  
Parallel

**Other design features**

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

committee of Kashan University of medical sciences

#### Street address

Ghotbe Ravandi Blvd

#### City

Kashan

#### Province

Isfahan

#### Postal code

8715988141

#### Approval date

2020-02-03, 1398/11/14

#### Ethics committee reference number

IR.KAUMS.MEDNT.REC.1398.129

## Health conditions studied

### 1

#### Description of health condition studied

Rheumatoid arthritis

#### ICD-10 code

M05

#### ICD-10 code description

Rheumatoid arthritis with rheumatoid factor

## Primary outcomes

### 1

#### Description

Hs-CRP

#### Timepoint

At the beginning of the study and after 12 weeks of intervention

#### Method of measurement

Elisa kit

### 2

#### Description

Glutathione

#### Timepoint

At the beginning of the study and after 12 weeks of intervention

#### Method of measurement

Spectrophotometry

### 3

#### Description

Total antioxidant capacity

#### Timepoint

At the beginning of the study and after 12 weeks of intervention

#### Method of measurement

Spectrophotometry

### 4

#### Description

Triglycerides

#### Timepoint

At the beginning of the study and after 12 weeks of

intervention  
**Method of measurement**  
Enzymatic kit

## 5

**Description**  
Fasting plasma glucose  
**Timepoint**  
At the beginning of the study and after 12 weeks of intervention  
**Method of measurement**  
Enzymatic kit

## 6

**Description**  
HDL  
**Timepoint**  
At the beginning of the study and after 12 weeks of intervention  
**Method of measurement**  
Enzymatic kit

## 7

**Description**  
Total cholesterol  
**Timepoint**  
At the beginning of the study and after 12 weeks of intervention  
**Method of measurement**  
Enzymatic kit

## 8

**Description**  
Nitric oxide  
**Timepoint**  
At the beginning of the study and after 12 weeks of intervention  
**Method of measurement**  
Spectrophotometry

## **Secondary outcomes**

empty

## **Intervention groups**

### 1

**Description**  
The intervention group will receive one Selenium tablet 200 microgram tablet daily for 12 weeks.  
**Category**  
Treatment - Drugs

### 2

**Description**  
The control group will receive one placebo tablet daily for 12 weeks.

**Category**  
Placebo

## **Recruitment centers**

### 1

**Recruitment center**  
**Name of recruitment center**  
Shahid Beheshti Hospital  
**Full name of responsible person**  
Batol Zamani  
**Street address**  
Qotb-e-Ravandi Boulevard  
**City**  
Kashan  
**Province**  
Isfahan  
**Postal code**  
8115187159  
**Phone**  
+98 31 5554 0026  
**Email**  
zamani-b@kaums.ac.ir

## **Sponsors / Funding sources**

### 1

**Sponsor**  
**Name of organization / entity**  
Kashan University of Medical Sciences  
**Full name of responsible person**  
Hamid Reza Banafshe  
**Street address**  
Qotbe Ravandi Blvd  
**City**  
Kashan  
**Province**  
Isfahan  
**Postal code**  
8715988141  
**Phone**  
+98 31 5554 0021  
**Email**  
research@kaums.ac.ir

**Grant name**  
**Grant code / Reference number**  
**Is the source of funding the same sponsor organization/entity?**  
Yes

**Title of funding source**  
Kashan University of Medical Sciences  
**Proportion provided by this source**  
100  
**Public or private sector**  
Public  
**Domestic or foreign origin**  
Domestic  
**Category of foreign source of funding**  
empty  
**Country of origin**

## Type of organization providing the funding

Academic

## Person responsible for general inquiries

### Contact

**Name of organization / entity**

Kashan University of Medical Sciences

**Full name of responsible person**

Fereshte Taghvae

**Position**

Associate

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Internal Medicine

**Street address**

Qhotbe Ravandi Blvd

**City**

Kashan

**Province**

Isfahan

**Postal code**

8115187159

**Phone**

+98 31 5554 0021

**Email**

fsh.taghvae@gmail.com

## Person responsible for scientific inquiries

### Contact

**Name of organization / entity**

Kashan University of Medical Sciences

**Full name of responsible person**

Nasrin Sharifi

**Position**

Consultant

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Nutrition

**Street address**

Qhotbe Ravandi Blvd

**City**

Kashan

**Province**

Isfahan

**Postal code**

8715988141

**Phone**

+98 31 5562 0608

**Email**

sharifi-na@kaums.ac.ir

## Person responsible for updating data

### Contact

**Name of organization / entity**

Kashan University of Medical Sciences

**Full name of responsible person**

Fereshte Taghvae

**Position**

Associate

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Internal Medicine

**Street address**

Ghotbe Ravandi Blvd

**City**

Kashan

**Province**

Isfahan

**Postal code**

8115187159

**Phone**

+98 31 5554 0021

**Email**

fsh.taghvae@gmail.com

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

Yes - There is a plan to make this available

**Study Protocol**

Undecided - It is not yet known if there will be a plan to make this available

**Statistical Analysis Plan**

Undecided - It is not yet known if there will be a plan to make this available

**Informed Consent Form**

Undecided - It is not yet known if there will be a plan to make this available

**Clinical Study Report**

Undecided - It is not yet known if there will be a plan to make this available

**Analytic Code**

Not applicable

**Data Dictionary**

Not applicable

**Title and more details about the data/document**

A portion of the data regarding demographics, anthropometric, and food variables, that are collected at the baseline of the study, and also the information on the main outcome will be shared.

**When the data will become available and for how long**

The start of the data access period will be one year after the publication of the result.

**To whom data/document is available**

Researchers working in academic institutions

**Under which criteria data/document could be used**

In order to conduct meta analysis studies

**From where data/document is obtainable**

Nasrin Sharifi, Nutrition Department, School of Medicine, Kashan University of Medical Sciences, Qotbe-e-Ravandi Blvd., Kashan, Iran Postal Code: 88715973474 E-mail: sharifi-na@kaums.ac.ir Tel: 00983155540021 Fax: 00983155620608

**What processes are involved for a request to access data/document**

An applicant can send a request for a data file by e-mail.

After reviewing the request, the data file will be sent to  
him/her after about three weeks would have passed from

the date of the request  
**Comments**